← Back to Screener
Oric Pharmaceuticals, Inc. Common Stock (ORIC)
Price$7.50
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-44.79%
Price vs S&P 500 (4W)-15.24%
VGM Score21.63
Market Capitalization$776.38M
All Metrics
Book Value / Share (Quarterly)$4.02
P/TBV (Annual)1.84x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.07
Price vs S&P 500 (YTD)-16.47%
EPS (TTM)$-1.43
10-Day Avg Trading Volume2.03M
EPS Excl Extra (TTM)$-1.43
EPS (Annual)$-1.47
ROI (Annual)-33.68%
Cash / Share (Quarterly)$2.72
ROA (Last FY)-31.66%
EBITD / Share (TTM)$-1.54
ROE (5Y Avg)-40.02%
Cash Flow / Share (Annual)$-1.13
P/B Ratio1.87x
P/B Ratio (Quarterly)3.06x
Net Income / Employee (Annual)$-1,244,900
ROA (TTM)-33.31%
EPS Incl Extra (Annual)$-1.47
Current Ratio (Annual)14.13x
Quick Ratio (Quarterly)15.86x
3-Month Avg Trading Volume1.80M
52-Week Price Return-18.12%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.54
52-Week High$14.93
EPS Excl Extra (Annual)$-1.47
CapEx CAGR (5Y)1.22%
26-Week Price Return-36.87%
Quick Ratio (Annual)13.79x
13-Week Price Return-45.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.33x
Enterprise Value$719.99M
Book Value / Share Growth (5Y)-13.15%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.86
3-Month Return Std Dev114.74%
Net Income / Employee (TTM)$-1,300,100
ROE (Last FY)-33.68%
EPS Basic Excl Extra (Annual)$-1.47
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.43
ROI (TTM)-35.33%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.93
Price vs S&P 500 (52W)-42.49%
Year-to-Date Return-8.31%
5-Day Price Return-16.48%
EPS Normalized (Annual)$-1.47
ROA (5Y Avg)-36.13%
Month-to-Date Return-11.24%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-1.61
ROI (5Y Avg)-40.02%
EPS Basic Excl Extra (TTM)$-1.43
P/TBV (Quarterly)1.65x
P/B Ratio (Annual)2.07x
Book Value / Share (Annual)$3.90
Price vs S&P 500 (13W)-54.10%
Beta1.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-35.33%
52-Week Low$7.23
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.34est. -0.33
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ORICOric Pharmaceuticals, Inc. Common Stock | — | — | D | $7.50 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies designed to overcome cancer resistance mechanisms across three focus areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company's pipeline includes product candidates ORIC-944, ORIC-114, and ORIC-533.